Castle Biosciences (CSTL) Payables (2018 - 2026)

Castle Biosciences has disclosed Payables across 9 years of filings, most recently posting $9.7 million for Q2 2026.

• In Q2 2026, Payables fell 26.65% year-over-year to $9.7 million; the TTM figure through Jun 2026 stood at $9.7 million (down 26.65% YoY), while the FY2025 annual figure was $18.7 million, up 171.13% from the prior year.
• Payables came in at $9.7 million for Q2 2026 at Castle Biosciences, down from $15.0 million in the prior quarter.
• In the past five years, Payables ranged from a high of $18.7 million in Q4 2025 to a low of $3.3 million in Q2 2022.
• Average Payables over 5 years is $9.0 million, with a median of $8.9 million recorded in 2024.
• Year-over-year, Payables surged 200.57% in 2023 and tumbled 32.79% in 2024.
• Over 5 years, Payables stood at $4.7 million in 2022, then soared by 117.04% to $10.3 million in 2023, then tumbled by 32.79% to $6.9 million in 2024, then jumped by 171.13% to $18.7 million in 2025, then tumbled by 48.33% to $9.7 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $9.7 million in Q2 2026, $15.0 million in Q1 2026, and $18.7 million in Q4 2025.